PRX-102 Leads to Improvement in Fabry Patients, Phase 1/2 Data Suggest
PRX-102 (pegunigalsidase alfa), Protalix BioTherapeutics’ investigational enzyme replacement therapy, led to clinical improvements in adults with Fabry disease, according to data from two Phase 1/2 trials. The therapy lowered both kidney globotriaosylceramide (Gb3) inclusions and blood levels of Gb3, showing that it reaches affected tissues, and…